ライフサイエンスコーパス: pegylation

1 (LLP2A-DOTA)(4)PEG(10,000) were prepared by PEGylation.

2 of PEG moieties attached, and the site(s) of PEGylation.

3 ed independent confirmation of the extent of pegylation.

4 resent in the circulation were unaffected by PEGylation.

5 e extended plasma half-life achieved through pegylation.

6 o be used for highly efficient site-specific PEGylation.

7 ood retention time was markedly prolonged by PEGylation.

8 s predicted from individual N- or C-terminal PEGylation.

9 -like liposomes with reduced cholesterol and pegylation.

10 thus serving as a potential alternative for PEGylation.

11 es of select cysteines using the kinetics of pegylation.

12 PEGylation also reduced the immunogenicity of rMETase.

13 Pegylation also reduced the tendency of the conjugate to

14 We combined both PEGylation and circularization by exploiting two distinc

15 ecular suture that allows both site-specific PEGylation and covalent closure.

16 Simultaneous PEGylation and fluorescent labeling of sCT is also demon

17 Protein PEGylation and PEG chain elimination occurred without ch

18 lpha molecule that is related to the site of pegylation and size of polyethylene glycol (PEG) attache

19 Using biogenic intermediates, mass tagging (pegylation), and a molecular tape measure, we explored t

20 asma pharmacokinetics with carboxyl-directed pegylation, and (ii) enable transport through the BBB by

21 ultiple attachment sites, solubility through PEGylation, and drug release through the use of pH-sensi

22 oped that when combined with methods such as pegylation antibody Fc attachment and binding to serum a

23 tal problems with the existing approaches to PEGylation are inefficient conjugation and the formation

24 s and Pluronics) and advances in the area of PEGylation as the most important bioconjugation strategy

25 First, PEGylation assays revealed that the AAP did not undergo

26 PEGylation assays using a cysteineless version of ArnT s

27 trast, after intravenous injection, targeted PEGylation at HVRs 1, 2, 5, and 7 increased viral liver

28 PEGylation at the C terminus retained the in vitro activ

29 PEGylation at Val-1(alpha) and at Val-1(beta) increase t

30 ich is at a higher level than that caused by PEGylation at Val-1(beta).

31 AM radicals can be easily derivatized (e.g., PEGylation) at the nine carboxylate groups and the resul

32 Initial pegylation attempts using lipid-poor apoAI showed a mark

33 In vitro, PEGylation blocked uptake of viruses via the Kupffer cel

34 on improves stability in a manner similar to PEGylation, but that the new conjugates retain or even i

35 Therefore, the pattern of PEGylation can be manipulated for the design of the PEGy

36 If PEGylation can be proved to promote evasion of microglia

37 Accordingly, the sites of PEGylation can determine the tetramer stability of the P

38 Results demonstrate that PEGylation can significantly improve the therapeutic ran

39 cation of proteins with polyethylene glycol (PEGylation) can increase plasma half-lives, stability, a

40 upled to each subunit of rMETase after hyper-PEGylation compared with 6-8 PEG chains attached to the

41 PEGylation completely abrogated coxsackievirus and adeno

42 Furthermore, after PEGylation, ConA's binding affinity to the fluorescent c

43 Thus, the molecular modification of PEGylation confers critical new properties to rMETase fo

44 of beta receptor subunit binding by adjacent PEGylation could be responsible for the altered biologic

45 PEGylation decreased the transfection efficacy by at lea

46 tio, hydrophobe (BMA) placement, and surface PEGylation density was correlated to important outcomes

47 d corona-forming polymers (indirectly tuning PEGylation density) and identification of a ternary nano

48 Although PEGylation did extend the beta-elimination circulation h

49 irmed the assigned structure and showed that pegylation did not disrupt the hydrogen-bonded ridge-til

50 the pharmacokinetic profiles, indicate that PEGylation does protect the virus from inactivation in t

51 The design of the extension arm-facilitated PEGylation (EAFP) of proteins takes advantage of the hig

52 n termed "PEG-fluorochrome shielding", where PEGylation enhances quantum yields while blocking troubl

53 grafting polyethylene glycol onto particles (PEGylation) extend circulation times; however, these par

54 PEGylation extended the circulation half-life of active

55 tilizing bioengineering techniques including PEGylation, Fc fusion, and single-chain design.

56 ution study showed that LCP-II required more PEGylation for MPS evasion than the previous LPD, probab

57 rated in liposomes with different degrees of pegylation (FosPEG 2% and FosPEG 8%), following i.v. adm

58 esults of the present study demonstrate that PEGylation greatly prolongs serum half-life of the rMETa

59 The PEGylation had minimal effect on integrin-binding affini

60 PEGylation has been shown to increase the residence time

61 Subunit stabilization and PEGylation has thus produced a potential protein therape

62 PEGylation has turned proteins into important new biopha

63 ng of polyethylene glycol (PEG) to proteins (PEGylation) has become a standard method to prolong bloo

64 ng the polymer polyethylene glycol (PEG), or PEGylation, has brought more than ten protein drugs into

65 ion technologies including glycosylation and PEGylation have been developed to improve its pharmacoki

66 tion of the non-specific interaction via the PEGylation; (iii) tumor targeting via the MMP2-mediated

67 lysine groups on the surface of ConA (i.e., PEGylation) in an attempt to improve its stability in th

68 In addition, we show that PEGylation increases protein adsorption with our formula

69 three types of (198)Au-GNPs with or without PEGylation into mice; the gamma radiation in blood speci

70 PEGylation is a proven approach to prolonging the durati

71 Site-specific PEGylation is achieved with a bis-thiol alkylating PEG r

72 PEGylation is an attractive approach to modifying oligon

73 ly(ethylene glycol) (PEG) conjugation (i.e., PEGylation) is a commonly used strategy to increase the

74 Polyethylene glycol conjugation (PEGylation) is the most successful strategy to date to o

75 e prepared purified, homogeneous, positional pegylation isomers of IFN-alpha2b that were monopegylate

76 Pegylation led to more mitochondrial localization as sho

77 Initial results suggest that hyper-PEGylation may become a new strategy for PEGylation of p

78 ctivity and increased PEG size suggests that pegylation may interfere with interaction and binding of

79 entional methods often lead to heterogeneous PEGylation mixtures with reduced protein activity.

80 However, the effect of PEGylation needs to be carefully studied due to the obse

81 Chemical shift data suggest that pegylation occurs mainly at the N(delta)(1) position in

82 hydroxy-,N(omega)-methoxy-carbamoylation and pegylation of 4Aph at positions 5 and 6 (7-10, 15-17, 22

83 Taken together, these results suggest that pegylation of a polymer-photosensitizer conjugate improv

84 PEGylation of a protein can be completed in 24 h and pur

85 s is the first demonstration of non-covalent PEGylation of acylated peptides, an important biologic c

86 dition of ribavirin to alpha interferon, the pegylation of alpha interferon, and the demonstration th

87 PEGylation of an oligonucleotide using a brush polymer c

88 Pegylation of apoAI in rHDL markedly increases its plasm

89 fe in the circulation, we determined whether pegylation of apoAI or HDL would increase its plasma hal

90 PEGylation of biologics offers enhanced stability, durat

91 Therefore, the PEGylation of ConA can overcome major hurdles for ConA-b

92 e have successfully applied this approach to PEGylation of cytokines, enzymes, antibody fragments and

93 Pegylation of full-length Kv1.3, as well as Kv1.3 fragme

94 PEGylation of Hb at Cys-93(beta) perturbed the heme envi

95 In contrast, PEGylation of Hb at Val-1(beta) gives rise to less prono

96 PEGylation of human FGF21 at a specific and preferred si

97 However, pegylation of human holo-HDL or reconstituted phospholip

98 We hypothesized that PEGylation of IL-15 interferes with beta but not alpha r

99 Pegylation of introduced cysteines shows that the pore h

100 which lipid binding seems to protect against pegylation of key functional residues.

101 For site-specific PEGylation of LMB-2, one cysteine residue was introduced

102 In this study, we evaluated the effect of PEGylation of mesoporous silica nanorods (MSNR) on hemol

103 t DNA technology, site-directed mutagenesis, pegylation of molecules, peptide library screening, and

104 Pegylation of nanoparticles has been widely implemented

105 reporter fusions and sulfhydryl labelling by PEGylation of novel cysteine residues introduced into a

106 PEGylation of NP was done by including a PEG-phospholipi

107 This study showed that PEGylation of paclitaxel offers a potential delivery sys

108 PEGylation of peptides and proteins has been widely used

109 PEGylation of peptides and proteins presents significant

110 per-PEGylation may become a new strategy for PEGylation of protein biologics.

111 PEGylation of protein side chains has been used for more

112 Because pegylation of purified proteins is commonly used as a me

113 Site-specific PEGylation of recombinant immunotoxins may increase thei

114 in vivo half-life depended on the extent of PEGylation of rMETase.

115 d for the successful site-specific and rapid pegylation of sCT.

116 with small unilamellar vesicles (SUVs), 10% PEGylation of the formulation could influence liposome r

117 PEGylation of the glycine-serine linker was used to enha

118 PEGylation of the photosensitizer construct was found to

119 PEGylation of the RTNs enhanced luciferase transfection

120 ns of MW similar to that of PEG, used in the PEGylation of therapeutic proteins, can be employed.

121 We performed random TMS(PEG)12 PEGylation of tTF-NGR to improve the antitumor profile o

122 The PEGylation of very low O2 affinity Hbs is now contemplat

123 nized with neutralizing anti-VSV antibodies, PEGylation of VSV improved the persistence of VSV in the

124 Pegylation of wortmannin and 17-hydroxywortmannin gives

125 ormed a molecular recognition of DCL- and AG-PEGylation on ligand binding on PSMA active site.

126 A negative effect of PEGylation on MTX loading was observed but PEGylated MSN

127 bination of reduced vesicle size and surface pegylation on the biodistribution and adjuvanticity of t

128 ut could do little to identify the extent of pegylation or to support characterization of the consist

129 sing a microfluidic system) in analyzing the pegylation pattern of a recombinant protein over a range

130 teine-scanned S6 transmembrane segment using pegylation (PEG-MAL) and calmodulation (CaM-MAL).

131 sic, and 1,20-eicosanedioic acid showed that pegylation per se has little, if any, effect on carboxyl

132 We found that PEGylation prevented dose-dependent hemolysis in the con

133 s work illustrates a novel means of specific PEGylation, producing FGF21 analogs with high specific a

134 Pegylation prolongs the serum concentration of IL-10 wit

135 tion of antibodies for fluorescent labeling, PEGylation, protein cross-linking, immunoliposome format

136 Our PEGylation protocol solves these problems by exploiting

137 A novel traceless reversible protein PEGylation reagent is developed based on thioester chemi

138 We also report that PEGylation reduced, but did not eliminate, the populatio

139 For example, PEGylation reduces the immunogenicity of protein cage-ba

140 PEGylation resulted in an approximately 2-log step decre

141 The pegylation results in lower in vitro specific activity a

142 Finally, PEGylation showed a reduction in electrostatic-induced a

143 light scattering measurements indicate that PEGylation significantly improved ConA's thermal stabili

144 ectly predicts the location of a stabilizing PEGylation site within the chicken Src SH3 domain.

145 owever, in the absence of a specific protein PEGylation site, chemical conjugation is inherently hete

146 potency and in vivo efficacy and provides a PEGylation site.

147 We hypothesize that globally optimal PEGylation sites are characterized by the ability of the

148 developed a method to increase the number of PEGylation sites in a model protein, recombinant methion

149 thereby may prove an alternative to covalent PEGylation strategies.

150 The site of pegylation strongly influenced activity relative to an I

151 he possibility of using modern site-specific PEGylation techniques to install PEG oligomers at predet

152 into the T1-T1 interface had lower rates of pegylation than cytosolic-facing cysteines, namely, C5 i

153 and the anti-IL-17A Fab' benefited more from PEGylation than the anti-IL-13 Fab' did.

154 tribution of sites on proteins available for PEGylation (the N terminus and the -amino group of lysin

155 elivery strategies, including self-assembly, PEGylation, the enhanced permeability and retention effe

156 culating XTEN-AnxA5 without the necessity of PEGylation, thereby simplifying the synthesis while avoi

157 We demonstrate that after surface pegylation, these silica-coated magneto-fluorescent supe

158 were chosen in human FGF21 for site-specific PEGylation to ensure that receptor binding regions were

159 on assistant non-washing technique and shell PEGylation to reach high colloidal stability of drug nan

160 Attachment of polyethylene glycol (pegylation) to a polyacetylated conjugate between poly-l

161 itch of the protein material by high surface PEGylation under conservation of the native three-dimens

162 d anti-IL-13 Fab' fragments in the lungs but PEGylation was able to prolong their presence in both th

163 PEGylation was evaluated as a novel strategy for prolong

164 achment of long chained polyethylene glycol (PEGylation) was pursued.

165 To increase the extent of PEGylation, we have developed a method to increase the n

166 ral protein modification technologies beyond PEGylation were also highlighted.

167 methoxypoly(ethylene glycol) (mPEG), termed PEGylation, which has led to several clinically approved

168 esidues for antiviral activity and show that pegylation, which often increases a peptide's serum t(1/

169 nt blood-brain barrier passage of DT through PEGylation, which polarizes the molecule and increases i

170 Screening of variant expression level, PEGylation yield, and functional assay identified severa

171 cific C-terminal or dual (N- and C-terminal) PEGylation, yielding (18)F-FBA-A20FMDV2-PEG28 (4) and (1